Home/Pipeline/BB101 (part of BB10x program)

BB101 (part of BB10x program)

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Blue Bees Therapeutics

About Blue Bees Therapeutics

Blue Bees Therapeutics is an early-stage biotech developing novel immunotherapies for oncology based on a proprietary platform for creating bi-specific immunomodulatory antibodies. The company, spun out from CEA Paris-Saclay, holds an exclusive worldwide license for its core technology and is advancing its lead program, BB101, towards validation. Backed by SATT Paris-Saclay, private equity, and grants, it aims to address the limitations of current cancer immunotherapies, such as low response rates and side effects, by introducing new mechanisms of action.

View full company profile

Therapeutic Areas

Oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active